AGM
AUTL

Alpine Global Management’s Autolus Therapeutics AUTL Stock Holding History

Alpine Global Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,885
Closed -$38K – 169
2022
Q4 		$38K Buy
+19,885
New +$50.3K 0.01% 411

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Alpine Global Management's AUTL Position: Q1 2023 in Review

Alpine Global Management sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 19,885 shares — an estimated $38K sold.

Alpine Global Management first reported a position in AUTL in Q4 2022 and held it in 1 quarter. The position peaked at $38K in Q4 2022. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

  • Alpine Global Management reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 19,885 Autolus Therapeutics shares in Q1 2023, an estimated $38K.
  • Alpine Global Management first reported a position in Autolus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Autolus Therapeutics position peaked at $38K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.